Bayer 3Q Net Sales EU10.19B; Est. EU9.97B

Bayer, a German pharmaceuticals and chemicals giant, reported strong financial results, surpassing estimates in several areas. The company achieved higher-than-expected earnings before interest, tax, depreciation, and amortization (EBITDA) and net sales for the third quarter. As a result, Bayer raised its full-year forecast. The company is shifting its focus more towards healthcare, moving away from chemicals. Notably, the blood thinner drug Xarelto saw significant sales growth, and the Merck acquisition contributed positively to sales and EBITDA. Overall, Bayer's performance led to an upgrade in full-year expectations.

What was Bayer's reported EBITDA for the third quarter, excluding various items?

• €1.80 billion

• €2.50 billion

• €2.01 billion

• €1.95 billion

How did Bayer's net sales for the third quarter compare to estimates?

• They were not reported

• They were below estimates

• They matched the estimates

• They exceeded the estimates

What is the focus of Bayer's business shift?

• From agriculture to chemicals

• From pharmaceuticals to agriculture

• From chemicals to healthcare

• From healthcare to chemicals

What was the sales figure for Xarelto in the third quarter?

• €750 million

• €500 million

• €407 million

• €1 billion

How much did the Merck acquisition contribute to Bayer's fourth quarter sales?

• €100-150 million

• €300-350 million

• €200-250 million

• €400-450 million